Drug Profile


Alternative Names: Brintellix®; LU-AA21004; LuAA 21004; Trintellix

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lundbeck A/S
  • Developer Lundbeck A/S; Takeda
  • Class Antidepressants; Anxiolytics; Piperazines; Small molecules; Sulfides
  • Mechanism of Action Serotonin 1A receptor agonists; Serotonin 1B receptor agonists; Serotonin 1D receptor antagonists; Serotonin 3 receptor antagonists; Serotonin 7 receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder
  • Phase III Generalised anxiety disorder
  • Phase II Anxiety disorders; Attention-deficit hyperactivity disorder

Most Recent Events

  • 23 Jun 2017 Lundbeck and Takeda receives complete response letter from the US FDA for vortioxetine sNDA in the treatment of cognitive dysfunction in Major depressive disorder
  • 27 Apr 2017 Lundbeck completes a phase II trial in Major depressive disorder (Recurrent) in Finland, Slovakia, Lithuania, Estonia (PO) (IV) (NCT02919501)
  • 01 Sep 2016 Lundbeck completes a phase II trial in Attention-deficit hyperactivity disorder in USA (PO) (NCT02327013)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top